Edwards lifesciences reports q2 loss of $0.20 per share

‍​quarterly loss per share $0.20.‍​quarterly adjusted eps $0.34.‍​quarterly sales down 15% to $925 million.‍​quarterly global tavr sales $594 million, down 12% (down 11% on an underlying basis).q2 earnings per share view $0.17, revenue view $797.5 million -- refinitiv ibes data.‍​now sees fy adjusted eps $1.75 -$1.95; fy sales guidance reiterated.‍​announces fda approval to initiate pivotal study for evoque tricuspid replacement system.‍​tavr sales depressed in april as patients, providers turned focus to pandemic response.for ‍tavr, say steady improvement in procedure volumes throughout may and june.expects sales in q3 to return to 2019 levels, and to start growing again in q4.sees q3 total sales to be between $1.0 billion-1.2 billion.
EW Ratings Summary
EW Quant Ranking